CLS Americas announced it will debut its office-based, magnetic resonance (MR)/ultrasound (US) fusion-guided, TRANBERG Thermal Therapy System for high-precision focal laser ablation of soft tissue, such as prostate cancer tumours, at the American Urological Association (AUA) 2022 Conference (May 13–16, New Orleans, USA).
The system is designed to work with multiple MR/US fusion image guidance systems for precise and accurate ablation in a minimally invasive setting, while preserving healthy prostate tissue.
“CLS is pleased to introduce its office-based, fusion-guided TRANBERG Thermal Therapy System at this year’s AUA conference,” stated Michael Magnani, president of CLS Americas. “We are commercialising this innovative technology so that patients can benefit from being treated with focal laser ablation in a urology office or clinic instead of a hospital.”
“While treating prostate cancer tumours successfully is the primary goal, some current treatment options expose patients to unacceptably high risks of complications such as erectile dysfunction or urinary incontinence,” said Fernando J Bianco, investigator-in-chief for the Urological Research Network, and principal investigator of the Phase I clinical study running at Urological Research Network, Miami Lakes, USA. “Based on my initial clinical trial experience with the TRANBERG laser, I believe that partial gland fusion ablation provides the precision to successfully treat the cancerous lesions while offering patients a superior side effect profile. The ongoing study will provide us with more information on this.”
